Clinical Trails Post

September 2025 clinical trial highlights

by Pulmonary Fibrosis Foundation
September 19, 2025
September Header

Clinical trial participants are essential in the quest for new treatments and a cure for pulmonary fibrosis (PF).

Each month, we'll highlight a few of the many trials that are enrolling volunteers. To view more available trials for various forms of interstitial lung disease (ILD), please visit the 🔍 PFF Clinical Trial Finder.


Seeking participants with SSc-ILD

MOONSCAPE

Seeking participants with IPF

Study Evaluating INS018_055 Administered Orally to Subjects With IPF

Seeking participants for the PFF Community Registry

PFF Community Registry

Resource spotlight: PFF's Common Health Research Terms

This guide helps explain common health research terms you may come across, including types of research, types of clinical trials, clinical trial phases, and more.

Download the resource


Ambassador

Bill was shocked when what he thought was an ordinary physical revealed that he had PF. Although Bill had occasionally experienced slight wheezing, he did not expect that the doctor would listen to his breathing and inform him of such a serious diagnosis. After further tests, including a thoracic biopsy, Bill received the unexpected diagnosis of PF and hypersensitivity pneumonitis, an ILD related to environmental exposure. 

In response, Bill set new goals in his life: learn as much as he can about PF, contribute to research through clinical trials participation, support fellow patients living with PF by sharing information and motivating them with a positive attitude, and continuing to make lasting memories with friends and family. Today, Bill can often be found at support groups, advisory board meetings, as well as supporting PF research and fellow patients.

 


Perspectives of people living with IPF 

A new study using data from the PFF Registry and published in BMC Pulmonary Medicine reveals the challenges that people living with IPF are facing. It highlights areas that are in critical need of improvement, including: 

  • Awareness and education
  • The perceived impact of antifibrotics and the need for clearer treatment expectations
  • The need for coordinated care to manage multiple health conditions
  • The need for holistic support in managing the benefits and burdens of supplemental oxygen

“This study provided an opportunity to truly listen to patients, capturing their experiences with diagnosis, antifibrotic therapy, and oxygen use-areas where we know there are gaps in understanding and support,” said Dr. Shore, “These findings highlight the critical need for high-quality educational resources, to strengthen advocacy efforts, and to enhance collaboration with healthcare providers to ensure that patient voices remain at the center of care decisions.”

- Jessica Shore, PhD, RN, Senior Vice President of Clinical Affairs and Quality

You can still register for the largest conference on PF and ILD

As the PFF celebrates a milestone 25 years of funding groundbreaking research, uniting patients and professionals, and lighting the path toward a cure, it also prepares for its eighth highly anticipated PFF Summit conference. Set to take place in Chicago from November 13 to 15, the Summit underscores the Foundation's enduring legacy and future ambitions.

At the PFF Summit, you'll dive into the latest updates on research with activities such as the scientific poster presentations and sessions like "Research in the pipeline: What might the next 25 years hold?" In addition, the popular Clinical Trial Innovation Series makes a return to the Summit. In this two-part series, groundbreaking research takes the stage as trial sponsors report on the latest findings in clinical trials.

Register and learn more

 

If you have any questions or comments about this newsletter, please email partnerships@pulmonaryfibrosis.org.